Can venetoclax cure leukemia?

Venetoclax (Venetoclax) is an innovative targeted drug designed to treat certain types of leukemia, especially chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). While venetoclax has shown significant efficacy in clinical trials, particularly in response rates, it often does not completely cure leukemia.

For chronic lymphocytic leukemia (CLL), venetoclax induces cancer cell apoptosis by targeting the inhibition of the Bcell lymphoma-2 (BCL-2) protein. This treatment regimen, especially when combined with other drugs such as Obinutuzumab, has resulted in deep and even complete remissions in some patients. However, complete remission does not mean that the disease is cured, as leukemia is a complex and relapsing disease. Venetoclax can prolong patients' disease-free survival and improve their quality of life, but the long-term efficacy and possibility of cure still require further clinical research.

For acute myeloid leukemia (AML), venetoclax also shows potential, especially in patients who are older or who are not candidates for intensive chemotherapy. It is often combined with low-dose chemotherapy drugs such as azacitidine or decitabine and has shown higher response rates. But similar to CLL, cure rates for AML remain a challenge, especially in high-risk patients. Although venetoclax can significantly reduce the number of cancer cells and slow progression of the disease in many cases, most patients still require long-term maintenance treatment.

As a result, venetoclax plays a key role in the treatment of leukemia, especially in refractory or relapsed patients. Its main function is to prolong progression-free survival and reduce the burden of cancer cells, improving the patient's quality of life. Although it can achieve complete remission in many patients, complete cure of leukemia is less likely, especially in patients with acute leukemia. Further research and clinical trials are ongoing to optimize the therapeutic effects of venetoclax or to improve cure rates through combination therapy.